http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102526037-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_31f7f4d0fc807c98c145cd77018bf2eb |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-18 |
| filingDate | 2012-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a911d194bd7167705ffa4e4776340f66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c651c74a7ff0023e8601b2e7e23ad69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5de36d5989fa3c647e64401d4c83389b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fab2345c9df08ce3e844d894f5d8e78a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b318a0f81cbcec16359fea6cb94e273 |
| publicationDate | 2014-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102526037-B |
| titleOfInvention | Telmisartan medicinal composition, telmisartan medicinal composition tablets and preparation method for telmisartan medicinal composition tablets |
| abstract | The invention provides a telmisartan medicinal composition, telmisartan medicinal composition tablets and a preparation method for the telmisartan medicinal composition tablets. The composition consists of the following components: telmisartan sodium salt, sorbitol, polacrilin potassium, anhydrous calcium phosphate, lactose, microcrystalline cellulose and magnesium stearate. The invention provides a preparation method for the telmisartan sodium salt, reaction conditions are mild, few side reactions are performed, and the generated sodium salt has higher water solubility; meanwhile, the sorbitol in the medicine has a diuresis effect, and has a synergistic antihypertensive effect with telmisartan in human bodies, so that the therapeutic effect of the product is strengthened; and after the telmisartan is taken, the urinary albumin excretion rate (UAER) of patients with early diabetic nephropathy is remarkably reduced, so the telmisartan has a kidney protection effect. |
| priorityDate | 2012-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 134.